Provides a limitation on the use of state funds for stem cell projects or research to those projects of research having the greatest potential for near-term clinical benefit in human patients.
BILL NUMBER: S1512
TITLE OF BILL : An act to amend the public health law, in relation to limiting the use of state funding on certain stem cell projects and research
PURPOSE : To ensure that taxpayer funds for stem cell research are spent in the wisest possible manner.
SUMMARY OF PROVISIONS : Section 1 -- Adds a new section 265-f to the Public Health Law to limit state funding for stem cell research to the most reliable and effective methods of research.
Section 2 -- Effective date.
JUSTIFICATION : In 2007, the New York State Legislature approved funding for stem cell research and created the Empire State Stem Cell Board. This board was designed to oversee the funding and policy related to stem cell research in New York State.
This legislation will ensure that funding for stem cell research in New York State is spent in the wisest most sensible and most fiscally prudent manner.
LEGISLATIVE HISTORY : S.5268-A of 2007-2008
FISCAL IMPLICATIONS : Undetermined.
EFFECTIVE DATE : Immediately.
STATE OF NEW YORK ________________________________________________________________________ 1512 2009-2010 Regular Sessions IN SENATE February 2, 2009 ___________Introduced by Sens. DeFRANCISCO, VOLKER -- read twice and ordered print- ed, and when printed to be committed to the Committee on Health AN ACT to amend the public health law, in relation to limiting the use of state funding on certain stem cell projects and research THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM- BLY, DO ENACT AS FOLLOWS: Section 1. Section 265-f of the public health law is renumbered section 265-g and a new section 265-f is added to read as follows: S 265-F. APPROPRIATE USE OF FUNDS. FUNDS APPROPRIATED OR OTHERWISE MADE AVAILABLE PURSUANT TO THIS ARTICLE SHALL BE USED TO CONDUCT AND SUPPORT BASIC AND APPLIED RESEARCH TO DEVELOP TECHNIQUES FOR THE ISOLATION, DERIVATION, PRODUCTION, TESTING, AND HUMAN CLINICAL USE OF STEM CELL PROJECTS OR RESEARCH WHICH HAVE THE GREATEST POTENTIAL FOR NEAR-TERM CLINICAL BENEFIT IN HUMAN PATIENTS, AS EVIDENCED BY THE IMPROVEMENT IN ONE OR MORE HUMAN PATIENTS SUFFERING FROM ILLNESS OR INJURY, AS DOCUMENTED IN REPORTS BY PROFESSIONAL MEDICAL OR SCIENTIFIC ASSOCIATIONS OR IN PEER-REVIEWED MEDICAL OR SCIENTIFIC LITERATURE. S 2. This act shall take effect immediately.EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets [ ] is old law to be omitted. LBD02134-01-9